Heimspiel!!!
NEWS
Oramed Pharmaceuticals to Present at the IATI Israel Innovation Conference in Tel Aviv
By PR Newswire, May 19, 2014, 07:00:00 AM EDT
Vote up AAA
Oramed to Present on Tuesday, May 20, 2014, at 4:10 p.m. (IDT)
JERUSALEM, May 19, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP), a clinical-stage developer of oral delivery systems, announced today that Josh Hexter, Oramed's Chief Operating Officer and Vice President of Business Development, will present a corporate overview at the IATI Israel Innovation Conference/MIXiii taking place May 20-22, 2014, in Tel Aviv, Israel.
Conference and Presentation Details
IATI Biomed 2014 - Israel Innovation Conference MIXiii
Date: Tuesday, May 20, 2014
Time: 9:10am EDT/4:10pm local time
Location: Tel-Aviv Fairgrounds
The IATI Israel Innovation Conference follows the success of previous annual conferences that hosted over 7,000 industry players, engineers and scientists with approximately 1,500 participants from over 45 countries and an excess of 4,500 one-on-one meetings.
About the IATI Israel Innovation Conference (MIXiii)
The Israel Innovation Conference, formerly known as the IATI-BioMed Conference, will be the first in the world where Biomed and High-tech will join hands in a unique and exciting new international conference format. The IATI-BioMed conference has been Israel's premier life science conference showcasing the country's most advanced companies and technologies, now to incorporate High-tech into the mix of its successful format. Building on the great reputation established in previous years, MIXiii offers attendees and presenters a winning mix of industry keynote speakers, exciting and innovative company presentations, and three days of exhibition and networking opportunities.
For more information on the Israel Innovation Conference, the content of which is not part of this press release, please visit: http://mixiii.com/
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem'sHadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in separate Phase II clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering IND-enabling studies later this year.
For more information, the content of which is not part of this press release, please visit: http://www.oramed.com
Read more: http://www.nasdaq.com/press-release/...v-20140519-00132#ixzz32ATckITS |
Thread abonnieren
